All In MedTech

Device Trial Radar · NCT07725419

Transcutaneous Pulsed Radiofrequency for the Treatment of Diabetic Peripheral Neuropathy Pain

Can a Non-interventional Pulsed Radiofrequency Device Relieve Pain and Improve Function in Patients With Diabetic Neuropathy That Are Refractory to Medication? A Single Blind Randomized Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

92

Actual

Start

Dec 2016

Primary completion

Aug 2019

Study completion Aug 2019

Sponsor

Lead sponsor
Algiamed Technologies USA, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Xavant Technology (Pty) Ltd
First posted
Jul 24, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if a non-invasive, electrical pulsed radio frequency (PRF) device can relieve pain and improve function in patients suffering from diabetic nerve pain in their feet, known as pedal diabetic peripheral neuropathy. Patients with this condition often experience severe pain, burning sensations, numbness, and tingling. Current medications for diabetic nerve pain often have unwanted side effects or do not provide sufficient relief. In this single-blind, randomized trial, participants are assigned to receive either an active PRF treatment or a placebo (sham) treatment. Both treatments involve placing the device safely behind the knee (targeting the sciatic nerve) for 10 minutes, once a week for 3 weeks. The main question this study aims to answer is whether the active PRF treatment reduces nerve pain and symptoms significantly more than the placebo, measured by standard symptom questionnaires over a 6-month period.

Conditions

  • Diabetic Peripheral Neuropathic Pain (DPN)
  • Diabetic Peripheral Neuropathy
  • Diabetic Peripheral Neuropathic Pain

Interventions

  • NMS 460 Pulsed Radio Frequency DeviceDevice

    Active transcutaneous electrical pulsed radio frequency stimulation. The device is applied bilaterally at the sciatic nerve in the popliteal fossa for 10 minutes, once weekly for 3 consecutive weeks.

  • Placebo DeviceDevice

    A sham device designed to look and operate like the active device but delivering no therapeutic current. It is applied bilaterally at the sciatic nerve in the popliteal fossa for 10 minutes, once weekly for 3 consecutive weeks to mimic the active treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Neuropathic Pain and Symptoms as Measured by the DN4 TestTime frame: Baseline, prior to the third treatment (Week 3), and at 1, 3, and 6 months after the last treatment.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Centre for Diabetes and Endocrinology (CDE), Houghton

    Johannesburg, Gauteng, South Africa

  • Clinical Sites - West Johannesburg

    Johannesburg, Gauteng, South Africa

  • Diabetic Clinic at the Charlotte Maxeke Hospital

    Johannesburg, Gauteng, South Africa

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.